Fine mapping of chromosome 22q tumor suppressor gene candidate regions in astrocytomas

被引:25
作者
Hartmann, C
Nümann, A
Mueller, W
Holtkamp, N
Simon, M
von Deimling, A
机构
[1] Humboldt Univ, Dept Neuropathol, Berlin, Germany
[2] Univ Bonn, Med Ctr, Dept Neurosurg, D-5300 Bonn, Germany
关键词
astrocytoma; low-grade; glioblastoma; chromosome; 22q; LOH; EP300; MY018B; MKL1; tumor suppressor gene;
D O I
10.1002/ijc.11638
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Astrocytomas and glioblastomas are the most frequent primary brain tumors in adults. Mutations and altered expression of multiple genes have been found to contribute to the genesis of these tumors. However, many factors in the genesis of astrocytic gliomas are not resolved yet. The frequent losses on several chromosomes indicate the role of still unidentified tumor suppressor genes. Loss of heterozygosity (LOH) on 22q has been described in up to 30% of astrocytic tumors and may be associated with progression to anaplasia. In a first step, information from the nearly finished physical sequence of chromosome 22 were used to map LOH data from 22q deletion studies on different tumor entities to identify potential tumor suppressor gene candidate regions. Next, a series of 153 astrocytic gliomas was examined with 11 polymorphic markers spanning these regions. Forty-nine (32%) astrocytic gliomas exhibited LOH on 22q 17 (35%) of which lost heterozygosity for all markers and 32 (65%) of which carried interstitial or partial deletions. Two regions were identified on the physical DNA sequence. The centromeric region spans 3 Mb and the telomeric region 2.7 Mb. The reduced size of these regions now allows direct analysis of all genes included. We already performed mutation analysis on 4 candidate genes from these regions (MYO18B, DJ1042K10.2, MKL1 and EP300), but did not find any mutations in astrocytic tumors. (C) 2003 Wiley-Liss, Inc.
引用
收藏
页码:839 / 844
页数:6
相关论文
共 40 条
[1]  
Allione F, 1998, INT J CANCER, V75, P181, DOI 10.1002/(SICI)1097-0215(19980119)75:2<181::AID-IJC3>3.0.CO
[2]  
2-Q
[3]   Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome [J].
Bell, DW ;
Varley, JM ;
Szydlo, TE ;
Kang, DH ;
Wahrer, DCR ;
Shannon, KE ;
Lubratovich, M ;
Verselis, SJ ;
Isselbacher, KJ ;
Fraumeni, JF ;
Birch, JM ;
Li, FP ;
Garber, JE ;
Haber, DA .
SCIENCE, 1999, 286 (5449) :2528-2531
[4]  
BENDER B, 1994, BIOTECHNIQUES, V16, P204
[5]  
Biegel JA, 1999, CANCER RES, V59, P74
[6]  
Bryan EJ, 2000, INT J CANCER, V87, P798, DOI 10.1002/1097-0215(20000915)87:6<798::AID-IJC6>3.0.CO
[7]  
2-X
[8]   Mapping of a target region of allelic loss to a 0.5-cM interval on chromosome 22q13 in human colorectal cancer [J].
Castells, A ;
Ino, Y ;
Louis, DN ;
Ramesh, V ;
Gusella, JF ;
Rustgi, AK .
GASTROENTEROLOGY, 1999, 117 (04) :831-837
[9]  
Castells A, 2000, CANCER RES, V60, P2836
[10]   Mutations truncating the EP300 acetylase in human cancers [J].
Gayther, SA ;
Batley, SJ ;
Linger, L ;
Bannister, A ;
Thorpe, K ;
Chin, SF ;
Daigo, Y ;
Russell, P ;
Wilson, A ;
Sowter, HM ;
Delhanty, JDA ;
Ponder, BAJ ;
Kouzarides, T ;
Caldas, C .
NATURE GENETICS, 2000, 24 (03) :300-303